Literature DB >> 11011070

The pharmacology of latent inhibition as an animal model of schizophrenia.

P C Moser1, J M Hitchcock, S Lister, P M Moran.   

Abstract

The nature of the primary symptoms of schizophrenia and our lack of knowledge of its underlying cause both contribute to the difficulty of generating convincing animal models of schizophrenia. A more recent approach to investigating the biological basis of schizophrenia has been to use information processing models of the disease to link psychotic phenomena to their neural basis. Schizophrenics are impaired in a number of experimental cognitive tasks that support this approach, including sensory gating tasks and models of selective attention such as latent inhibition (LI). LI refers to a process in which noncontingent presentation of a stimulus attenuates its ability to enter into subsequent associations, and it has received much attention because it is widely considered to relate to the cognitive abnormalities that characterise acute schizophrenia. Several claims have been made for LI having face and construct validity for schizophrenia. In this review of the pharmacological studies carried out with LI we examine its claim to predictive validity and the role of methodological considerations in drug effects. The data reviewed demonstrate that facilitation of low levels of LI is strongly related to demonstrated antipsychotic activity in man and all major antipsychotic drugs, both typical and atypical, have been shown to potentiate LI using a variety of protocols. Very few compounds without antipsychotic activity are active in this model. In contrast, disruption of LI occurs with a wide range of drugs and the relationship with psychotomimetic potential is less clear. Although reversal of disrupted LI has also been used as a model for antipsychotic acticity, mostly using amphetamine-induced disruption, insufficient studies have been carried out to evaluate its claim to predictive validity. However, like facilitation, it is sensitive to both typical and atypical antipsychotic agents. The data we have reviewed here demonstrate that facilitation of LI and, perhaps to a lesser extent, reversal of disrupted LI fulfil the criteria for predictive validity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11011070     DOI: 10.1016/s0165-0173(00)00026-6

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  46 in total

Review 1.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 2.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

Review 3.  Dopamine-glutamate neuron projections to the nucleus accumbens medial shell and behavioral switching.

Authors:  Susana Mingote; Aliza Amsellem; Abigail Kempf; Stephen Rayport; Nao Chuhma
Journal:  Neurochem Int       Date:  2019-06-03       Impact factor: 3.921

4.  Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning.

Authors:  Philipp Singer; Catherine J Wei; Jiang-Fan Chen; Detlev Boison; Benjamin K Yee
Journal:  Behav Brain Res       Date:  2012-12-28       Impact factor: 3.332

5.  Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.

Authors:  Tatiana Lipina; Viviane Labrie; Ina Weiner; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

6.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

7.  Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia.

Authors:  Inna Gaisler-Salomon; Gretchen M Miller; Nao Chuhma; Sooyeon Lee; Hong Zhang; Farhad Ghoddoussi; Nicole Lewandowski; Stephen Fairhurst; Yvonne Wang; Agnès Conjard-Duplany; Justine Masson; Peter Balsam; René Hen; Ottavio Arancio; Matthew P Galloway; Holly M Moore; Scott A Small; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

8.  Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?

Authors:  Mariana Bendlin Calzavara; Wladimir Agostini Medrano; Raquel Levin; Sonia Regina Kameda; Monica Levy Andersen; Sergio Tufik; Regina Helena Silva; Roberto Frussa-Filho; Vanessa Costhek Abílio
Journal:  Schizophr Bull       Date:  2008-02-16       Impact factor: 9.306

9.  Reelin haploinsufficiency reduces the density of PV+ neurons in circumscribed regions of the striatum and selectively alters striatal-based behaviors.

Authors:  Martine Ammassari-Teule; Carmelo Sgobio; Filippo Biamonte; Cristina Marrone; Nicola B Mercuri; Flavio Keller
Journal:  Psychopharmacology (Berl)       Date:  2009-03-10       Impact factor: 4.530

Review 10.  Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia.

Authors:  Urs Meyer; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2009-03-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.